Biogen readies its app after BG-12 beats Copaxone in PhIII MS study Read...
Biogen readies its app after BG-12 beats Copaxone in PhIII MS study Fierce Biotech
View ArticleBiogen-Idec's BG-12 Shines At the Top of the Charts in the Treatment of...
Biogen-Idec's BG-12 Shines At the Top of the Charts in the Treatment of Relapsing-Remitting Multiple Sclerosis Bradenton Herald, FL
View ArticleBiogen Idec Inc (BIIB): Today's Featured Health Care Winner
Biogen Idec Inc (BIIB): Today's Featured Health Care Winner The Street
View Article7 Large-Cap Biotech Equities With Strong Momentum Right Now
7 Large-Cap Biotech Equities With Strong Momentum Right Now Seeking Alpha
View ArticleBiogen Idec to Report Fourth Quarter & Year End 2011 Financial Results on...
Biogen Idec to Report Fourth Quarter & Year End 2011 Financial Results on January 31, 2012 Yahoo/BusinessWire
View ArticleIs Biogen's Stock Reasonable by the Numbers?
Is Biogen's Stock Reasonable by the Numbers? Motley Fool
View ArticleNew Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s...
New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec’s Commitment to Deliver Promising Therapies for Unmet Needs in Neurodegenerative Diseases Yahoo/BusinessWire
View ArticleNoteworthy Insider Buys And Sells In The Healthcare Sector
Noteworthy Insider Buys And Sells In The Healthcare Sector Seeking Alpha
View ArticleBiogen Idec Reaches New 52-Week High (BIIB)
Biogen Idec Reaches New 52-Week High (BIIB) The Street
View ArticleBiogen slips as FDA extends review of MS drug
Biogen slips as FDA extends review of MS drug Yahoo/AP
View Article2013 Should Be Interesting for Multiple Sclerosis Drugs
2013 Should Be Interesting for Multiple Sclerosis Drugs The Motley Fool
View ArticleBiogen Reveals Pricing For New MS Drug Tecfidera
Biogen Reveals Pricing For New MS Drug Tecfidera Forbes
View ArticleBiogen prices new MS drug at discount to key competitors
Biogen prices new MS drug at discount to key competitors Reuters
View ArticleBiogen Hits Primary Endpoints in MS Study
Biogen Hits Primary Endpoints in MS Study Motley Fool
View ArticleBiogen's MS Pill Roars Out Of Launch Gate
Biogen's MS Pill Roars Out Of Launch Gate TheStreet.com
View ArticleIBD 50: Top 5 Medical Stocks Include Celgene, Actavis
IBD 50: Top 5 Medical Stocks Include Celgene, Actavis Investors Business Daily
View Article
